WeTrials
Recruiting

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

What is this study?

This early-stage study tests a new radioactive drug combined with standard chemotherapy and targeted radiation. It aims to prepare adults with high-risk blood cancers for a successful donor stem cell transplant by safely destroying remaining cancer cells.

Who can participate?

Adults diagnosed with certain high-risk blood cancers, such as acute leukemias or myelodysplastic syndrome, may be eligible. Participants must be able to carry out normal daily activities and meet specific age and medical history requirements.

What will happen?

Participants will receive the new targeted radioactive treatment along with standard chemotherapy and precise radiation before undergoing a donor stem cell transplant. The study also involves routine tests like blood draws, bone marrow checks, and heart scans to monitor safety and progress.

Where and when?

This study is currently recruiting participants in Duarte, California, United States.

Key Points
  • 1Tests a new radioactive drug combined with transplant preparation treatments
  • 2Aims to improve outcomes for patients with high-risk blood cancers
  • 3Involves getting a donor stem cell transplant along with careful health monitoring

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.